In 2026, researchers and clinicians are developing new tools to help people recover. Whether you’re exploring options for yourself or a loved one, understanding these new tools can help you make informed decisions about care. Here’s a plain-language look at the most promising developments.
GLP-1 Medications: A Surprising New Contender
GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) were originally developed for diabetes and weight loss, but early research suggests they may also reduce cravings for alcohol and opioids. One large analysis of health records found that people with alcohol use disorder who took GLP-1 medications had substantially greater reductions in alcohol use than similar patients who did not receive these medications, and lower rates of alcohol intoxication events have been reported in some real‑world cohorts. Early observational data and trial plans in people with opioid use disorder also suggest that GLP-1 drugs may be associated with fewer overdoses, though this is still being actively studied.
Researchers believe these effects occur because GLP-1 acts on brain pathways involved in both appetite and reward-seeking behavior; preclinical and human studies suggest these medications dampen the rewarding effects of alcohol and other drugs. In simple terms, these medications seem to blunt the “reward signal” that drives cravings. While the early findings are promising, GLP-1s are not yet FDA-approved specifically for addiction, and larger clinical trials are underway to determine how they should be used in standard treatment plans.
Long-Acting Medications on the Horizon
For many people, managing daily medication-assisted treatment is a challenge. That’s why researchers are working on longer-acting options:
- One-year naltrexone implant: A titanium implant designed to release naltrexone steadily for up to 12 months is being developed with support from the NIH HEAL Initiative, with early human studies underway and researchers aiming for regulatory review in the next few years.
- Nor-LAAM: Scientists at Virginia Commonwealth University are studying a long-acting metabolite that is being reformulated into biodegradable microparticles designed for monthly dosing.
- Fentanyl vaccines: Teams at the University of Houston and the University of Montana are advancing vaccines designed to block fentanyl from reaching the brain, with Phase 1 human trials planned or underway.
These innovations aim to provide more stable protection against relapse, as past studies of extended‑release naltrexone implants have already suggested.
Mindfulness: Evidence-Based Support for Cravings
Mindfulness-based therapy has moved from a wellness buzzword into an evidence-based component of addiction treatment. Programs like Mindfulness-Based Relapse Prevention (MBRP) have shown reductions in substance use and distress across multiple meta-analyses.
In 2025, a major clinical trial published in JAMA Network Open followed adults receiving buprenorphine treatment; those assigned to an online mindfulness program reported a much larger reduction in opioid cravings than those in standard support groups. These findings suggest that adding structured mindfulness training can help people feel more in control of urges and improve overall quality of life.
A Shift Toward Compassion and Personalized Care
Modern approaches increasingly frame addiction as a chronic medical condition influenced by trauma and social context. Evidence-based models such as DBT-SUD focus on collaboration and dignity, with randomized controlled trials supporting its use for complex cases. Clinicians are also being encouraged to practice “cultural humility,” an approach that improves trust and retention in care.
Telehealth Continues to Expand Access
The expansion of telehealth has permanently reshaped delivery. Policy changes allow many patients to start buprenorphine through virtual visits. Studies in JAMA Network Open show that telemedicine can maintain or even improve engagement without increasing overdose risk. As federal rules evolve through 2026, telehealth is expected to remain a core part of the treatment landscape.
If you or someone you love is considering treatment, the toolbox is bigger than ever. Asking providers about these newer options can help you find a plan that fits your life.
